"Intermountain launches groundbreaking study using the PreTRM test to prevent preterm birth." Read more here


"Women want good information. If a test predicts that they might have a preterm birth, they want to know."


PreTRM Test Featured in Top-Tiered Scientific Journal as Example of Proteomic Test That Advances Patient Care. Read More


"The value of the PreTRM test cannot be overestimated. We continue to deal with the vast majority of women who eventually go into preterm labor and deliver early with having absolutely no identifiable risk factors." Watch Dr. Shulman's video here


“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO


"With 1 in 10 women in the United States delivering prematurely, I believe every woman is an excellent candidate for the PreTRM test." Watch Dr. Mandel's video here


Intermountain Healthcare Launches New Study to Determine Benefit of Proactive Interventions in Reducing Premature Births

May 29, 2018 - Intermountain Healthcare announced it is launching the first study of its kind that will use Sera's PreTRM® to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery. Read More >

Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology

Seattle, WA and Salt Lake City, February 12 - Sera Prognostics, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, "The building blocks of successful translation of proteomics to the clinic," by Leroy Hood and colleagues published online in Current Opinion in Biotechnology. Read More >

Sera Prognostics Announces Analytical Validation Study

SALT LAKE CITY, June 26, 2017– Sera Prognostics, Inc., a women’s healthcare company, announced today that its recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers. This work confirms Sera’s ability, across instrument generations, to perform accurate analytical measurements required to provide individualized determination of a woman’s risk of spontaneous early delivery through Sera’s groundbreaking PreTRM® test. The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk. Read More >


Our Goals

Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.